Ποια είναι η τιμή για IntelGenx Technologies Corp. (IGX)

Η τιμή για IntelGenx Technologies Corp. (IGX) είναι $0.17446996

Ποια είναι η κεφαλαιοποίηση αγοράς για IntelGenx Technologies Corp. (IGX)

Η κεφαλαιοποίηση αγοράς για IntelGenx Technologies Corp. (IGX) είναι $26.97M

IntelGenx Technologies Corp. (IGX) Τιμή και Κεφαλαιοποίηση Αγοράς

IntelGenx Technologies Corp. is a pharmaceutical drug delivery enterprise focused on the creation and manufacturing of advanced oral thin film products. The company's diverse product pipeline encompasses various oral film formulations designed to address a wide spectrum of medical conditions. These include INT0008/2008, a Rizatriptan film for migraine management; INT0046/2018 for adult applications; INT0007/2006, an oral film targeting erectile dysfunction; INT0043/2015, a montelukast-based film for Alzheimer's disease; INT0027/2011, intended for opioid addiction treatment; INT0010/2006, addressing neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, formulated for schizophrenia or bipolar I disorder; and INT0048/2020, developed for veterinary health. Additionally, IntelGenx is actively developing other candidates identified as INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has established strategic partnerships, including a comprehensive licensing, development, and supply agreement with Tilray, Inc., alongside a development pact with Cynapsus Therapeutics Inc. Founded in 2003, IntelGenx Technologies Corp. is headquartered in Montreal, Canada.

Η τιμή για IGX	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$34,286.40 $26.97M	NVDA	$5.301T	+19,651,650.21%
$29,972.20 $26.97M	AAPL	$4.634T	+17,178,901.33%
$26,797.10 $26.97M	GOOG	$4.143T	+15,359,049.45%
$23,216.32 $26.97M	MSFT	$3.589T	+13,306,674.86%
$18,478.95 $26.97M	AMZN	$2.857T	+10,591,380.69%

Η τιμή για IGX

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$34,286.40 $26.97M